Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary central nervous system lymphoma: essential points in diagnosis and management.

Literature DB >> 28315229

Primary central nervous system lymphoma: essential points in diagnosis and management.

Abstract

Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.

Entities: Chemical Disease Gene

Keywords: Chemotherapy; Management; Pathogenesis; Primary central nervous system lymphoma; Prognosis; Radiotherapy

Mesh：

Year: 2017 PMID： 28315229 DOI： 10.1007/s12032-017-0920-7

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

159 in total

1. Oncogenically active MYD88 mutations in human lymphoma.

Authors: Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal: Nature Date: 2010-12-22 Impact factor: 49.962

Review 2. Primary central nervous system lymphoma in patients with AIDS.

Authors: A Ruiz; M J Post; C Bundschu; W I Ganz; M Georgiou
Journal: Neuroimaging Clin N Am Date: 1997-05 Impact factor: 2.264

3. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors: L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal: Neurosurgery Date: 2000-01 Impact factor: 4.654

4. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Authors: Antonio Omuro; Olivier Chinot; Luc Taillandier; Hervé Ghesquieres; Carole Soussain; Vincent Delwail; Thierry Lamy; Rémy Gressin; Sylvain Choquet; Pierre Soubeyran; Aymeri Huchet; Alexandra Benouaich-Amiel; Sophie Lebouvier-Sadot; Emmanuel Gyan; Valérie Touitou; Maryline Barrié; Monica Sierra del Rio; Alberto Gonzalez-Aguilar; Caroline Houillier; Daniel Delgadillo; Lucette Lacomblez; Marie Laure Tanguy; Khê Hoang-Xuan
Journal: Lancet Haematol Date: 2015-06-03 Impact factor: 18.959

Review 5. Primary vitreoretinal lymphoma: an update on pathogenesis, diagnosis and treatment.

Authors: David Reichstein
Journal: Curr Opin Ophthalmol Date: 2016-05 Impact factor: 3.761

6. MRI findings of primary CNS lymphoma in 26 immunocompetent patients.

Authors: Dong Zhang; Liang-Bo Hu; Tobias D Henning; Elisabeth M Ravarani; Li-Guang Zou; Xiao-Yuan Feng; Wen-Xian Wang; Li Wen
Journal: Korean J Radiol Date: 2010-04-29 Impact factor: 3.500

7. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors: Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440

8. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.

Authors: G Illerhaus; R Marks; F Müller; G Ihorst; F Feuerhake; M Deckert; C Ostertag; J Finke
Journal: Ann Oncol Date: 2008-10-26 Impact factor: 32.976

9. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.

Authors: L Fischer; P Martus; M Weller; H A Klasen; B Rohden; A Röth; B Storek; M Hummel; T Nägele; E Thiel; A Korfel
Journal: Neurology Date: 2008-09-30 Impact factor: 9.910

10. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors: James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544

6 in total

1. Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.

Authors: Samantha S Soldan; Chenhe Su; R Jason Lamontagne; Nicholas Grams; Fang Lu; Yue Zhang; James D Gesualdi; Drew M Frase; Lois E Tolvinski; Kayla Martin; Troy E Messick; Jonathan T Fingerut; Ekaterina Koltsova; Andrew Kossenkov; Paul M Lieberman
Journal: PLoS Pathog Date: 2021-06-09 Impact factor: 6.823